Traders sold shares of Express Scripts Holding Co. (NASDAQ:ESRX) on strength during trading on Thursday. $18.78 million flowed into the stock on the tick-up and $97.94 million flowed out of the stock on the tick-down, for a money net flow of $79.16 million out of the stock. Of all companies tracked, Express Scripts Holding had the 0th highest net out-flow for the day. Express Scripts Holding traded up $0.38 for the day and closed at $76.17

Several research firms have recently commented on ESRX. Credit Suisse Group AG restated a “buy” rating on shares of Express Scripts Holding in a research note on Saturday, June 4th. Zacks Investment Research upgraded Express Scripts Holding from a “hold” rating to a “buy” rating and set a $81.00 price target for the company in a research note on Thursday, May 5th. Barclays PLC upped their price target on Express Scripts Holding from $85.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 27th. Mizuho upped their price target on Express Scripts Holding from $77.00 to $82.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 2nd. Finally, FBR & Co cut their price target on Express Scripts Holding from $90.00 to $75.00 and set a “mkt perform” rating for the company in a research note on Wednesday, April 27th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $81.26.

The firm has a 50-day moving average of $76.92 and a 200-day moving average of $72.94. The firm has a market cap of $48.02 billion and a PE ratio of 18.83.

Express Scripts Holding (NASDAQ:ESRX) last announced its earnings results on Monday, July 25th. The company reported $1.57 earnings per share for the quarter, meeting the consensus estimate of $1.57. During the same period in the previous year, the firm earned $1.44 EPS. The business had revenue of $25.20 billion for the quarter, compared to the consensus estimate of $25.42 billion. The firm’s revenue was down .9% on a year-over-year basis. Analysts predict that Express Scripts Holding Co. will post $6.38 EPS for the current fiscal year.

Other hedge funds have recently bought and sold shares of the company. Veritas Asset Management LLP increased its stake in Express Scripts Holding by 6.1% in the fourth quarter. Veritas Asset Management LLP now owns 3,334,367 shares of the company’s stock worth $291,457,000 after buying an additional 192,267 shares in the last quarter. Atlantic Trust Group LLC increased its stake in Express Scripts Holding by 0.3% in the fourth quarter. Atlantic Trust Group LLC now owns 1,786,315 shares of the company’s stock worth $156,141,000 after buying an additional 5,045 shares in the last quarter. Schroder Investment Management Group increased its stake in Express Scripts Holding by 5.7% in the fourth quarter. Schroder Investment Management Group now owns 1,365,089 shares of the company’s stock worth $119,322,000 after buying an additional 73,533 shares in the last quarter. Principal Financial Group Inc. increased its stake in Express Scripts Holding by 6.4% in the fourth quarter. Principal Financial Group Inc. now owns 1,026,443 shares of the company’s stock worth $89,721,000 after buying an additional 61,792 shares in the last quarter. Finally, Morningstar Investment Services LLC increased its stake in Express Scripts Holding by 12.5% in the fourth quarter. Morningstar Investment Services LLC now owns 401,192 shares of the company’s stock worth $35,068,000 after buying an additional 44,540 shares in the last quarter.

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.